Therapy Areas: Vaccines
4basebio announces expansion of DNA offering for personalised mRNA medicines
7 September 2026 - Synthetic DNA 4basebio PLC (AIM: 4BB) declared on Monday that it has expanded its DNA offering to support production of critical starting material for personalised mRNA medicines.Th...
Clover Biopharmaceuticals reports positive Phase 2 trial data for respiratory combination vaccine candidates
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia eva...
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
7 September 2026 - Rznomics Inc (KOSDAQ: 476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, on Monday announced a breakthrough in the h...
EpiVax introduces AI-enhanced models for immunogenicity prediction
3 September 2026 - EpiVax Inc, a provider of immunogenicity assessment and sequence optimisation for biologic therapeutics and vaccines, announced on Wednesday the release of AI-enabled enhancements t...
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
28 August 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) and German biotechnology company BioNTech SE (NASDAQ:BNTX) announced on Thursday that the US Food and Drug Administration (FDA) has ...
4basebio announces strategic collaboration with Genezen
26 August 2026 - Biotechnology company 4basebio PLC (AIM: 4BB) announced on Wednesday that it has signed a non-exclusive Strategic Collaboration and Marketing Agreement with gene therapy CDMO Genezen ...